Blue Jet Healthcare (BLUEJET) Fundamentals 2026 — P/E 40.8x, Revenue Analysis | SniperIQ
Blue Jet Healthcare (BLUEJET) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹10,095 Crore, trading at ₹584.80 on the BSE. This SniperIQ fundamentals page covers Blue Jet Healthcare's valuation (P/E 40.8x, P/B 7.4x), profitability (net margin 26.2%), revenue (₹947 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Blue Jet Healthcare's market cap?
Blue Jet Healthcare (BLUEJET) has a market capitalization of approximately ₹10,095 Crore, trading at ₹584.80 on the BSE. Market cap moves with the live share price.
What is Blue Jet Healthcare's P/E ratio?
Blue Jet Healthcare's trailing twelve-month P/E ratio is 40.8x, with a price-to-book (P/B) of 7.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Blue Jet Healthcare?
Blue Jet Healthcare runs a net profit margin of 26.2%, a gross margin of 46.1%, and an operating margin of 28.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Blue Jet Healthcare generate?
Blue Jet Healthcare reported revenue of ₹947 Crore for fiscal year 2026, with net income of ₹248 Crore and earnings per share (EPS) of 14.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Blue Jet Healthcare pay a dividend?
Blue Jet Healthcare offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Blue Jet Healthcare financially healthy?
Blue Jet Healthcare carries a debt-to-equity ratio of 0.03x and a current ratio of 4.21x, with a market beta of 0.77. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Blue Jet Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Blue Jet Healthcare (BLUEJET) the key facts are: market cap ₹10,095 Crore, P/E 40.8x, revenue ₹947 Crore, 52-week range 325.2-881.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Blue Jet Healthcare's full fundamentals live
Get Blue Jet Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.